Navigation Links
Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
Date:1/22/2008

testosterone levels, minimal excursions outside of the normal range, and an extremely high percentage of patients maintaining a eugonadal (normal) testosterone range. NEBIDO met its primary endpoints, a responder analysis based on average testosterone concentrations during the steady state dosing interval and an outlier analysis based on the maximum testosterone concentrations during the steady state dosing interval. As with the original dosing regimen, treatment with NEBIDO was well tolerated with this new dosing regimen.

"As we have previously stated, we have been evaluating dosing regimens that we believe optimize the replacement of testosterone in men with hypogonadism. I am extremely pleased that the dosing regimen evaluated in this study accomplishes this objective," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The results of our trial demonstrate a rapid achievement of steady-state testosterone levels, the maintenance of levels within the eugonadal range, and reductions in excursions above the normal range. Steady state testosterone pharmacokinetics were achieved within just weeks under the new regimen, whereas the 1000 mg regimen, while successfully achieving all primary objectives, reached steady state pharmacokinetics after several months of treatment."

Dr. Cooper continued, "We intend to ask for approval of this new 750 mg regimen, rather than the 1000 mg regimen, as we believe this new regimen distinguishes itself by providing physicians with the optimal long-term dosing solution for treating their male patients with hypogonadism. Importantly, we are extremely pleased with the feedback we recently received from the FDA that the PDUFA target action date was likely to remain unchanged."

Study Design

The most recent Phase III pharmacokinetic trial was an open-label (unblinded) study that evaluated treatment with an initial 750 mg of NEBIDO given via intramuscular injection, followed 4-weeks lat
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Submission of New Drug Application
3. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  An international roster ... Saturday, May 18, in Santa Monica, Calif. ... new lung-sparing therapies for MPM, a rare form of ... affects the pleura, the lining of the chest. ... and Blood Institute, the 3rd Annual International Symposium on ...
(Date:5/24/2013)... 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), ... today that Dr. Robert Grieve , the ... Napolitano , executive vice president and chief financial officer, ... is being held May 30, 2013 in New ... The Company,s presentation is scheduled to begin at ...
(Date:5/24/2013)... 2013 China Biologic Products, Inc. (Nasdaq: CBPO, ... plasma-based biopharmaceutical company in China , ... a public announcement issued by Shanghai RAAS Blood Products ... Shenzhen Stock Exchange, that on May 21, 2013, Ms. ... one of the shareholders of the Company, and her ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4
(Date:5/24/2013)... Chronic Fatigue Syndrome has been a mysterious ... fatigue lasting 6 months or longer. Symptoms of Chronic ... impairment, muscle and joint pain without swelling or redness, ... malaise that lasts for more than 24 hours. ... linked to insulin resistance. At a healthy body weight, ...
(Date:5/24/2013)... Today marks the launch of Destination Halifax’s latest ... The redesigned and enhanced Itinerary Builder will help visitors ... computer or mobile device that they can send, save, ... to fill in their date of arrival and length ... of vacation packages, accommodations, restaurants, and things to do ...
(Date:5/24/2013)... May 24, 2013 Bridal Buy ... to announce new 2013 bridesmaid dresses are ... bridesmaid dresses are handcrafted, featured as fine fabrics, elegant ... dress takes great skill and an eye for detailed ... hand-made embroidery, brought to life from patterns and the ...
(Date:5/24/2013)... The leading retail brand Short Dresses ... short prom dresses . Now that is quite unbelievable, especially ... the brand name since its origin. The retailer has already ... now this huge discount offer will be an added bonanza ... highly privileged to announce that Short Dresses is to offer ...
(Date:5/23/2013)... FL (PRWEB) May 24, 2013 ... the Cellulite Whisperer line, with a ... for Summer Sale" includes two proprietary products, the ... Whisperer® Lotion . , Purchasers receive a report ... , "The Gel has a wonderful grapefruit scent," ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 3Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:short prom dresses Offers Abnormally Low Discount on Its New Collections 2Health News:Fresh Organics in the New Cellulite Whisperer® Products from Sublime Beauty®; "Get Ready for Summer Sale" Continues 2
... study conducted by researchers say it is a misconception ... older or housebound people.// ,Researchers examined 150 ... levels of vitamin D. Among the participants, all African-American, ... D deficiencies, as were all patients younger than 30. ...
... A pitch-black room may be the healthiest environment for your ... at night // may put children at risk for ... to disrupt the circadian rhythm and suppress the production of ... been shown to protect DNA from oxidative damage. Once damaged, ...
... study shows sinusitis in asthma patients tends to be ... suggest patients // can have dramatic improvement in symptoms ... is used. ,In the study patients with asthma ... polyps, olfactory dysfunction, and nasal congestion compared to patients ...
... new study shows moderate consumption of alcohol may cut ... arteries.// Researchers evaluated 225 men after they had undergone ... open blocked arteries with a stent. Less traumatic than ... cause inflammation resulting in renarrowing of the artery, usually ...
... study researchers say the antidepressant duloxetine, also known ... fibromyalgia in women . Duloxetine works by stopping ... of the brain’s neurotransmitters that are linked to ... that is characterized by body pain, muscle tenderness, ...
... cluster of risk factors known as metabolic syndrome is ... risk factors. // ,Metabolic syndrome has been ... coronary heart disease. Metabolic syndrome includes looking at factors ... has two different definitions including one by the National ...
Cached Medicine News:
Modified Freer periosteal elevator, #163, slight curve, 21 cm....
Cottle periosteal & skin elevator, 7 1/2", slightly curved blade, 9 mm wide....
Steinhauser periosteal elevator....
Alley periosteal elevator, extra long, 21 cm, 8-1/4"....
Medicine Products: